BiotechTube
Foundation Medicine

Foundation Medicine

Cambridge, United States· Est.
foundationmedicine.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $279.9M

Overview

Foundation Medicine, founded in 2010 and headquartered in Cambridge, Massachusetts, is a commercial-stage diagnostics company and a global leader in comprehensive genomic profiling for oncology. Its flagship products, FoundationOne®CDx (tissue-based) and FoundationOne®Liquid CDx (blood-based), are FDA-approved companion diagnostics that analyze hundreds of genes to match advanced cancer patients with targeted therapies, immunotherapies, and clinical trials. As a wholly owned subsidiary of Roche since 2018, the company leverages its extensive genomic database, scientific expertise, and regulatory capabilities to support drug development for biopharma partners and integrate precision medicine into standard clinical workflow.

Oncology

Technology Platform

Proprietary next-generation sequencing (NGS) assays for comprehensive genomic profiling (CGP) from tissue (FoundationOne®CDx) and blood (FoundationOne®Liquid CDx), supported by a clinical laboratory, bioinformatics pipeline, and curated knowledgebase for companion diagnostic reporting.

Funding History

4
Total raised:$279.9M
IPO$106.4M
Series C$106M
Series B$42.5M
Series A$25M

Opportunities

Significant growth is driven by the expanding number of biomarker-driven therapies, increasing clinical guideline recommendations for comprehensive genomic profiling, and the rapid adoption of minimally invasive liquid biopsy testing.
Global expansion through Roche's infrastructure and leveraging its large genomic database for discovery and development present substantial opportunities.

Risk Factors

Faces intense competition from other diagnostic firms and academic labs, alongside ongoing challenges with insurance reimbursement and regulatory requirements.
As a subsidiary, strategic direction and integration within the larger Roche organization could impact agility and focus.

Competitive Landscape

Foundation Medicine competes in the comprehensive genomic profiling market with companies like Guardant Health (liquid biopsy focus), Thermo Fisher Scientific (Oncomine Dx Target Test), and Illumina (via Grail). Its key competitive advantages are its extensive FDA-approved companion diagnostic portfolio, integration with Roche's therapeutic pipeline, and its large, established clinical database.

More companies in Diagnostics & Precision Medicine →More companies in United States →